Molecular structure of Lorglumide Sodium, CAS Number: 1021868-76-7
Lorglumide Sodium (CAS 1021868-76-7)
See product citations (1)
Alternate Names:
CR 1409
Application:
Lorglumide Sodium is a specific cholecytokinin receptor antagonist
CAS Number:
1021868-76-7
Purity:
≥98%
Molecular Weight:
481.39
Molecular Formula:
C22H31Cl2N2NaO4
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
* Refer to Certificate of Analysis for lot specific data.
QUICK LINKS
Ordering Information
Product Citations
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
Lorglumide Sodium is a specific cholecytokinin receptor antagonist which inhibits the effects of cholecytokinin on pancreatic growth, as well as the development of pancreatic lesions and chemically induced carcinogenesis.
Lorglumide Sodium (CAS 1021868-76-7) References
- Antianalgesic action of dynorphin A mediated by spinal cholecystokinin. | Rady, JJ., et al. 1999. Proc Soc Exp Biol Med. 220: 178-83. PMID: 10193446
- Involvement of cholecystokinin receptor in the inhibition of gastrointestinal motility by estradiol in ovariectomized rats. | Wu, CL., et al. 2002. Scand J Gastroenterol. 37: 1133-9. PMID: 12408516
- Pharmacological effects of oxytocin on gastric emptying and intestinal transit of a non-nutritive liquid meal in female rats. | Wu, CL., et al. 2003. Naunyn Schmiedebergs Arch Pharmacol. 367: 406-13. PMID: 12690433
- Enterostatin inhibition of dietary fat intake is dependent on CCK-A receptors. | Lin, L., et al. 2003. Am J Physiol Regul Integr Comp Physiol. 285: R321-8. PMID: 12855414
- Effects of cholecystokinin and bombesin on development of azaserine-induced pancreatic tumours in rats: modulation by the cholecystokinin receptor antagonist lorglumide. | Meijers, M., et al. 1992. Carcinogenesis. 13: 1525-8. PMID: 1394835
- Dopamine D2 receptor antagonism suppresses tau aggregation and neurotoxicity. | McCormick, AV., et al. 2013. Biol Psychiatry. 73: 464-71. PMID: 23140663
- Effect of cholecystokinin analogue caerulein and cholecystokinin antagonist lorglumide on pancreatic carcinogenesis in the rat. | Sperti, C., et al. 1994. J Surg Oncol. 57: 11-6. PMID: 8065144
- Inhibitory effect of a cholecystokinin antagonist on pancreatic carcinogenesis after pancreatobiliary diversion. | Watanapa, P., et al. 1993. Br J Cancer. 67: 663-7. PMID: 8471422
- Involvement of different subtypes of cholecystokinin receptors in opioid antinociception in the mouse. | Suh, HW., et al. 1995. Peptides. 16: 1229-34. PMID: 8545243
- Effects of cholecystokinin-B receptor antagonist on dopamine system in tenascin mutant mice. | Fukamauchi, F., et al. 1997. Neuroreport. 8: 3919-22. PMID: 9462466
Inhibitor of:
CCK-AR, and Cholecystokinin Receptor.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
Lorglumide Sodium, 25 mg | sc-205734 | 25 mg | $165.00 | |||
Lorglumide Sodium, 100 mg | sc-205734A | 100 mg | $650.00 |